Cargando…

Phase 1/2 study of PRO1160, a CD70-directed antibody-drug conjugate, in patients with advanced solid tumors and hematologic malignancies

Background: PRO1160 is a novel antibody-drug conjugate (ADC) directed to CD70, an antigen mediating immuno-suppression that is overexpressed in multiple solid tumors and hematologic malignancies, with limited distribution in normal tissues. PRO1160 comprises (1) a human monoclonal antibody specific...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jonasch, Eric, Call, Justin, Kambhampati, Swetha, Caimi, Paolo, Curti, Brendan, Diefenbach, Catherine, Heath, Elisabeth, Park, Steven, Kornblum, Noah, Li, Weidong, Reimers, Melissa, Spurgeon, Stephen, Vaishampayan, Ulka, Ye, Dingwei, Zhang, Li, Zhao, Weili, Chen, Zhu, Hunder, Naomi, Ma, Sharon, Song, Eric, Garmezy, Benjamin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Trials in Progress Abstract Presentations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10445573/ http://dx.doi.org/10.1093/oncolo/oyad216.024

Ejemplares similares

1160. Ecological Study for Pulmonary Blastomycosis
por: Wang, James L, et al.
Publicado: (2020)

Benign Cutaneous Cysts: A Comprehensive Analysis of 1160 cases
por: Chughtai, Anila, et al.
Publicado: (2023)

Clinical Activity and Safety of Cediranib and Olaparib Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma without BRCA Mutation
por: Kim, Joseph W., et al.
Publicado: (2021)

Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy‐Naive Metastatic Castrate‐Resistant Prostate Cancer
por: Heath, Elisabeth, et al.
Publicado: (2019)

Treatment of Indian Kala-Azar with a New Antimony Compound: Nu-1160
por: Gupta, P. C. Sen, et al.
Publicado: (1952)

The Year in Review for Renal Cancer
por: Vaishampayan, Ulka
Publicado: (2020)

The power of meta-analysis in therapeutic decision making for advanced kidney cancer
por: Vaishampayan, Ulka
Publicado: (2019)

Phase 1b/2 trial of Ipilimumab, Nivolumab, and Ciforadenant (INC) (adenosine A2a receptor antagonist) in first-line advanced renal cell carcinoma
por: Beckermann, Kathryn, et al.
Publicado: (2023)

Development of cabozantinib for the treatment of prostate cancer
por: Vaishampayan, Ulka N
Publicado: (2014)

1160. Infrequency of Respirator Change Following Annual Respiratory Fit Testing at an Academic Medical Center
por: Chuang, Tzu-Ying, et al.
Publicado: (2018)

A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors
por: Michaelson, M. Dror, et al.
Publicado: (2019)

A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer
por: Fong, Lawrence, et al.
Publicado: (2021)

Supratentorial Cerebral Arterial Territories for Computed Tomograms: A Mapping Study in 1160 Large Artery Infarcts
por: Kim, Dong-Eog, et al.
Publicado: (2019)

P1160: RESULTS OF A PHASE 2 EXPANDED ACCESS STUDY OF ZANUBRUTINIB IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA
por: Castillo, J. J., et al.
Publicado: (2022)

Optimized outcome prediction in breast cancer by combining the 70-gene signature with clinical risk prediction algorithms
por: Drukker, C. A., et al.
Publicado: (2014)

Limiting systemic endocrine overtreatment in postmenopausal breast cancer patients with an ultralow classification of the 70-gene signature
por: Opdam, M., et al.
Publicado: (2022)

First evidence of human‐to‐dog transmission of SARS‐CoV‐2 B.1.160 variant in France
por: Medkour, Hacène, et al.
Publicado: (2021)

Patients’ perceptions of 70-gene signature testing: commonly changing the initial inclination to undergo or forego chemotherapy and reducing decisional conflict
por: van Steenhoven, Julia E. C., et al.
Publicado: (2020)

Predictors of Cytoreductive Nephrectomy for Metastatic Kidney Cancer in SEER and Metropolitan Detroit Databases
por: Vaishampayan, Ulka, et al.
Publicado: (2019)

Successful surgical treatment of a 1160 g neonate with cardiac teratoma and severe foetal hydrops: a case report
por: Beichl, Matthias, et al.
Publicado: (2021)

Immunotherapy and Immune Evasion in Prostate Cancer
por: Thakur, Archana, et al.
Publicado: (2013)

1160: PERCUTANEOUS GASTROSTOMY PLACEMENT IN PATIENTS WITH COVID-19 INFECTION: CLINICAL OUTCOMES AND THE INFREQUENT NEED FOR LONG-TERM ENTERAL ACCESS
por: Levine, Irving, et al.
Publicado: (2022)

1160. Comparative Effectiveness of Pneumococcal Vaccination Strategies to Prevent Invasive Pneumococcal Disease: A Cohort Study at the Veterans Health Administration
por: Goto, Michihiko, et al.
Publicado: (2023)

STARLITE 1: Phase 1b/2 study of combination 177Lu girentuximab plus cabozantinib and nivolumab in treatment naïve patients with advanced clear cell RCC
por: Hasanov, Elshad, et al.
Publicado: (2023)

Zanzalintinib in combination with immune checkpoint inhibitors: Design of the renal cell carcinoma expansion stage cohorts in STELLAR-002
por: Motzer, Robert J, et al.
Publicado: (2023)

P1160: METHOTREXATE IN COMBINATION WITH IBRUTINIB, THIOTEPA, RITUXIMAB (R-MTO) FOLLOWED BY AUTOLOGOUS STEM-CELL TRANSPLANT FOR PRIMARY CNS LYMPHOMA
por: Xing, LI-Jie, et al.
Publicado: (2023)

Exceptional pathologic complete response achieved with androgen deprivation and docetaxel therapy in Gleason 10 prostate cancer
por: Vaishampayan, Ulka, et al.
Publicado: (2019)

Pilot Phase II Trial of Bevacizumab Monotherapy in Nonmetastatic Castrate-Resistant Prostate Cancer
por: Ogita, Shin, et al.
Publicado: (2012)

A Phase 1/2, open label dose-escalation and expansion trial of NKT2152, an orally administered HIF2α inhibitor, to investigate safety, PK, PD and clinical activity in patients with advanced ccRCC
por: Jonasch, Eric, et al.
Publicado: (2023)

Overcoming difficulties with equipoise to enable recruitment to a randomised controlled trial of partial ablation vs radical prostatectomy for unilateral localised prostate cancer
por: Elliott, Daisy, et al.
Publicado: (2018)

Exploring patients’ experience and perception of being diagnosed with bladder cancer: a mixed‐methods approach
por: Tan, Wei Shen, et al.
Publicado: (2020)

CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin‐C vs surgical management in low‐risk non‐muscle‐invasive bladder cancer
por: Mostafid, A. Hugh, et al.
Publicado: (2020)

The ProtecT trial: analysis of the patient cohort, baseline risk stratification and disease progression
por: Bryant, Richard J., et al.
Publicado: (2020)

Diagnostic accuracy, clinical utility and influence on decision‐making of a methylation urine biomarker test in the surveillance of non‐muscle‐invasive bladder cancer
por: D'Andrea, David, et al.
Publicado: (2019)

In‐hospital cost analysis of prostatic artery embolization compared with transurethral resection of the prostate: post hoc analysis of a randomized controlled trial
por: Müllhaupt, Gautier, et al.
Publicado: (2019)

Ultra‐hypofractionated radiation therapy for unfavourable intermediate‐risk and high‐risk prostate cancer is safe and effective: 5‐year outcomes of a phase II trial
por: Macias, Victor A., et al.
Publicado: (2019)

Phase I Study of Anti-CD3 x Anti-Her2 Bispecific Antibody in Metastatic Castrate Resistant Prostate Cancer Patients
por: Vaishampayan, Ulka, et al.
Publicado: (2015)

Overcoming Obstacles in Liquid Biopsy Developments for Prostate Cancer
por: Jang, Albert, et al.
Publicado: (2022)

70740 Impact of fundus pigmentation on retinal layer visibility on investigational bedside optical coherence tomography in preterm infants
por: Seely, Kai R., et al.
Publicado: (2021)

Tolerability and safety of GS-101 eye drops, an antisense oligonucleotide to insulin receptor substrate-1: a ‘first in man’ Phase I investigation
por: Kain, Hermann, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_s0rc3e4k9s25fdc24e1ajbfvkd